New research from the University of Chicago found that many middle-aged and older Americans with diabetes are sexually active but more likely to experience sexual problems compared with counterparts without diabetes...

Palatin Technologies, Inc. (NYSE Amex: PTN) announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD)...

Novacare LLC has announced that it is conducting a voluntary nationwide recall of products sold under the following names: Stiff Nights, Aziffa, Size Matters, Erex, Mojo, Hard Drive, Eyeful, Red Magic, Straight Up, Zotrex, Monster Excyte, WOW, Xaitrex, Verect, Prolatis, Xytamax, Maxyte, Libidinal, OMG, OMG45, and Zilex (with Golden Spear)...

EZVille, Ltd. of Ronkonkoma, NY, has been informed by the US Food and Drug Administration (FDA) that FDA lab analysis of Revivexxx® Extra Strength distributed by the company was found to contain undeclared tadalafil. Tadalafil is an FDA-approved drug for the treatment of male Erectile Dysfunction (ED), making Revivexxx® Extra Strength an unapproved drug...

One of the challenges of prostate cancer surgery is removing the cancer-affected gland without side effects. The procedure is estimated to cause long-term sexual dysfunction in half of men...

UroToday.com - Peyronie's disease (PD) occurs more frequently following radical prostatectomy (RP) than it does among men in the general population, according to a report by Dr. Raanan Tal and colleagues in the Journal of Sexual Medicine. In the general population, the incidence of PD is reported to be 3.2-8.9%...

UroToday.com - Erectile Dysfunction (ED) is the most common male sexual dysfunction presented for treatment, and the most thoroughly studied sexual dysfunction in men. In the late 20th century, important discoveries were made regarding both the physiologic processes of penile erection and the pathophysiology of ED...

At the request of the U.S. Food and Drug Administration, U.S. Marshals seized $346,954.43 worth of FastSize Extender devices and FastSize EQM Erectile Quality Monitor devices, as well as component parts used in the manufacture of the FastSize Extender. The FastSize Extender and the FastSize EQM Erectile Quality Monitor are manufactured and distributed by FastSize, LLC of Aliso Viejo, Calif...

Research carried out by a visiting professor at the University of Hertfordshire has found that up to six million European men fail to seek help for Erectile Dysfunction (ED) which could result in underlying cardiovascular disease going undetected...

A new study in the Journal of Sexual Medicine found that the presence of depressive symptoms in men with erectile dysfunction constitutes a risk factor for a major cardiovascular event. Erectile dysfunction and depressive mood are often associated, and both are associated with an increased risk of cardiovascular disease and death...

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) announced that the United States Patent and Trademark Office issued a patent on May 18, 2010, for the method for treatment of premature ejaculation using dapoxetine. Furiex developed dapoxetine in collaboration with Alza Corporation and its affiliates. U.S. Patent No...

Physicians who prescribe erectile dysfunction drugs for their male patients should be sure to discuss the importance of safer sex practices, even with older patients: that is an important implication of a report in the July 6 issue of Annals of Internal Medicine. The analysis of insurance records of more than 1.4 million U.S...

NexMed, Inc. (Nasdaq: NEXMD), a specialty CRO with a pipeline of product candidates based on the NexACT® technology, announced that the Japanese Patent Office has issued the Decision to Grant a Patent for NexMed's patent application entitled, "Prostaglandin Compositions for the Treatment of Male Erectile Dysfunction...

Seven out of 10 men admitted to hospital for a heart attack (acute ST segment elevation myocardial infarction (STEMI)) had erectile dysfunction (ED) in the six months prior to their admission according to new data presented at the World Congress of Cardiology (WCC) Scientific Sessions in Beijing, China...

After men have surgery to remove a cancerous prostate gland, up to 80 percent of them will lose the ability to have an erection because of damage to a critical nerve that runs along the prostate. New research from Northwestern University Feinberg School of Medicine shows the damaged nerve can be regenerated more quickly with a protein called sonic hedgehog delivered via a nanofiber gel...

Given that it is not clear whether male menopause actually exists, and inconclusive evidence on testosterone's effectiveness in treating it, an article in today's Drug Therapeutics Bulletin (DTB), a BMJ (British Medical Journal) journal, says that the use of synthetic testosterone is questionable...

Physician-scientists from NewYork-Presbyterian Hospital/Weill Cornell Medical Center presented their latest research findings at the American Urological Association's Annual Meeting in San Francisco, May 29 to June 3. Dr. Steven Kaplan, a urologist and professor of urology at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, and Dr...

VIVUS, Inc. (Nasdaq: VVUS) announced that data from the previously reported phase 3 pivotal REVIVE (TA-301) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED), were presented at the American Urological Association (AUA) 2010 Annual Meeting...

In the largest study to date evaluating erectile dysfunction (ED) and coronary artery calcification, researchers at Mount Sinai School of Medicine have determined that men with ED are at a significantly increased risk of high coronary artery calcification scores (CACS), a known predictor of future cardiovascular events...

Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., presented data summarizing the results of two pivotal studies of the investigational new drug PSD502, a topical metered dose spray being developed for the treatment of primary premature ejaculation (PE). These data were presented at the 2010 American Urological Association (AUA) Annual Meeting in San Francisco...